270 related articles for article (PubMed ID: 23867769)
21. Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.
Salamone JD; Betz AJ; Ishiwari K; Felsted J; Madson L; Mirante B; Clark K; Font L; Korbey S; Sager TN; Hockemeyer J; Muller CE
Front Biosci; 2008 May; 13():3594-605. PubMed ID: 18508458
[TBL] [Abstract][Full Text] [Related]
22. Oral tremor induced by the muscarinic agonist pilocarpine is suppressed by the adenosine A2A antagonists MSX-3 and SCH58261, but not the adenosine A1 antagonist DPCPX.
Collins LE; Galtieri DJ; Brennum LT; Sager TN; Hockemeyer J; Müller CE; Hinman JR; Chrobak JJ; Salamone JD
Pharmacol Biochem Behav; 2010 Feb; 94(4):561-9. PubMed ID: 19958787
[TBL] [Abstract][Full Text] [Related]
23. Dose-dependent effects of adenosine antagonists on tacrine-induced tremulous jaw movements.
Johnson JA; Montgomery AP; Starr ER; Ludwig J; Trevitt J
Eur J Pharmacol; 2018 Aug; 833():364-369. PubMed ID: 29883670
[TBL] [Abstract][Full Text] [Related]
24. Blockade of adenosine A
Kosmowska B; Ossowska K; Wardas J
Behav Brain Res; 2022 Jan; 417():113585. PubMed ID: 34536428
[TBL] [Abstract][Full Text] [Related]
25. Effects of cabergoline and rotigotine on tacrine-induced tremulous jaw movements in rats.
Koganemaru G; Abe H; Kuramashi A; Ebihara K; Matsuo H; Funahashi H; Yasuda K; Ikeda T; Nishimori T; Ishida Y
Pharmacol Biochem Behav; 2014 Nov; 126():103-8. PubMed ID: 25265240
[TBL] [Abstract][Full Text] [Related]
26. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
[TBL] [Abstract][Full Text] [Related]
27. Effect of subtype-selective adenosine receptor antagonists on basal or haloperidol-regulated striatal function: studies of exploratory locomotion and c-Fos immunoreactivity in outbred and A(2A)R KO mice.
Pardo M; López-Cruz L; Valverde O; Ledent C; Baqi Y; Müller CE; Salamone JD; Correa M
Behav Brain Res; 2013 Jun; 247():217-26. PubMed ID: 23557694
[TBL] [Abstract][Full Text] [Related]
28. The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.
Yohn SE; Thompson C; Randall PA; Lee CA; Müller CE; Baqi Y; Correa M; Salamone JD
Psychopharmacology (Berl); 2015 Apr; 232(7):1313-23. PubMed ID: 25323625
[TBL] [Abstract][Full Text] [Related]
29. Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.
Salamone JD; Correa M; Carlson BB; Wisniecki A; Mayorga AJ; Nisenbaum E; Nisenbaum L; Felder C
Life Sci; 2001 Apr; 68(22-23):2579-84. PubMed ID: 11392629
[TBL] [Abstract][Full Text] [Related]
30. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.
Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD
Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139
[TBL] [Abstract][Full Text] [Related]
31. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.
Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M
Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
[TBL] [Abstract][Full Text] [Related]
33. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission.
Andersson DR; Nissbrandt H; Bergquist F
Eur J Neurosci; 2006 Jul; 24(2):617-24. PubMed ID: 16903863
[TBL] [Abstract][Full Text] [Related]
34. Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of Parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243.
Salamone JD; Carlson BB; Rios C; Lentini E; Correa M; Wisniecki A; Betz A
Behav Brain Res; 2005 Jan; 156(2):173-9. PubMed ID: 15582103
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor.
Collins-Praino LE; Paul NE; Rychalsky KL; Hinman JR; Chrobak JJ; Senatus PB; Salamone JD
Front Syst Neurosci; 2011; 5():49. PubMed ID: 21772815
[TBL] [Abstract][Full Text] [Related]
36. Extracellular GABA in globus pallidus increases during the induction of oral tremor by haloperidol but not by muscarinic receptor stimulation.
Collins-Praino LE; Podurgiel SJ; Kovner R; Randall PA; Salamone JD
Behav Brain Res; 2012 Sep; 234(1):129-35. PubMed ID: 22728308
[TBL] [Abstract][Full Text] [Related]
37. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M
J Neurol Sci; 2006 Oct; 248(1-2):48-52. PubMed ID: 16780890
[TBL] [Abstract][Full Text] [Related]
38. The novel adenosine A2A antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade.
Collins LE; Sager TN; Sams AG; Pennarola A; Port RG; Shahriari M; Salamone JD
Pharmacol Biochem Behav; 2012 Jan; 100(3):498-505. PubMed ID: 22037410
[TBL] [Abstract][Full Text] [Related]
39. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration.
Kuribara H
Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603
[TBL] [Abstract][Full Text] [Related]
40. Injections of the selective adenosine A2A antagonist MSX-3 into the nucleus accumbens core attenuate the locomotor suppression induced by haloperidol in rats.
Ishiwari K; Madson LJ; Farrar AM; Mingote SM; Valenta JP; DiGianvittorio MD; Frank LE; Correa M; Hockemeyer J; Müller C; Salamone JD
Behav Brain Res; 2007 Mar; 178(2):190-9. PubMed ID: 17223207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
